Document Type : Original Article
Authors
- Zahra Mirfeizi 1
- Mandana Khodashahi 1
- Aryan Seyedhosseini 2
- Amirreza Bagheri 2
- Hossein Ghazaee 2
- Maryam Kiani 3
- Mobina Sayadizadeh 4
- Sara Samadi 5
1 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Internal Medicine, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
4 Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
5 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background: Systemic lupus erythematosus (SLE) is a long-term autoimmune condition characterized by diverse clinical and laboratory manifestations influenced by genetic, environmental, and socioeconomic factors. This study aimed to characterize the clinical and laboratory profiles of SLE in Iranian patients.
Methods: A cross-sectional study was conducted on patients with SLE at a private rheumatology clinic from 2015 to 2023. Data on clinical manifestations and laboratory findings, including immunological indices, systemic inflammation, hematological, metabolic, thyroid, and renal factors, were collected from patient medical records.
Results: Of 313 patients (284 females, 29 males; mean age: 43.68 ± 12.39 years for females, 40.20 ± 10.17 years for males), the most prevalent clinical manifestations were joint pain (61.94%) and skin rash (60%). Renal, vascular, serositis, neuropsychiatric, and cardiac manifestations occurred in 33.33%, 17.15%, 9.39%, 7.44%, and 2.91% of patients, respectively. Leukopenia was observed in 24.10%, thrombocytopenia in 10.13%, and all patients were ANA-positive. Gender differences included higher leukopenia in females (25.63% vs. 10.34%; P=0.041) and elevated LDL in males (25% vs. 9.6%; P=0.014).
Conclusion: This study delineates the clinical and laboratory characteristics of SLE in Iranian patients, revealing patterns consistent with global cohorts but shaped by regional genetic and environmental factors. Comparisons with international studies highlight the influence of ethnicity on disease presentation, emphasizing the need for tailored management and prospective research to address data gaps, such as histopathological and serological details.
Keywords
Main Subjects
- Narváez J. Systemic lupus erythematosus 2020. Med Clin (Barc) 2020;155(11):494–501. doi:10.1016/j.medcli.2020.05.009
- Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules 2021;11(7):928. doi:10.3390/biom11070928
- Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annu Rev Med 2023;74:339–52. doi:10.1146/annurev-med-043021-032611
- Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017;12(5):825–35. doi:10.2215/ cjn.05780616
- Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015;11(6):329–41. doi:10.1038/nrneph.2015.33
- Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2019;96:1–13. doi:10.1016/j.jaut.2018.11.001
- Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis 2017;76(12):1992–2000. doi:10.1136/ annrheumdis-2017-211206
- Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017;56(11):1945–61. doi:10.1093/ rheumatology/kex260
- Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford) 2017;56(suppl_1):i67–i77. doi:10.1093/rheumatology/ kew399
- Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15–29. doi:10.1136/ard-2023-224762
- D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369(9561):587–96. doi:10.1016/ s0140-6736(07)60279-7
- Tekeoglu S, Temiz Karadag D, Ozdemir Isik O, Yazici A, Cefle A. Analysis of clinical, immunological characteristics, damage, and survival in 300 Turkish systemic lupus erythematosus patients. Lupus 2024;33(3):298–311. doi:10.1177/09612033241228174
- Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005;4(5):296–302. doi:10.1016/j.autrev.2005.01.003
- Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64(9):1366–9. doi:10.1136/ard.2004.033100
- Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009;18(5):465–73. doi:10.1177/0961203308100660
- Chung YK, Ho LY, Lee C, To CH, Mok CC. Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients. Ther Adv Musculoskelet Dis 2022;14:1759720x221100300. doi:10.1177/1759720x221100300
- Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023;82(3):351– 6. doi:10.1136/ard-2022-223035
- Barber MRW, Falasinnu T, Ramsey-Goldman R, Clarke AE. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology (Oxford) 2023;62(Suppl 1):i4–i9. doi:10.1093/ rheumatology/keac610
- Bolla E, Semb AG, Kerola AM, Ikdahl E, Petri M, Pons-Estel GJ, et al. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries. Lancet Rheumatol 2024;6(7):e447–e59. doi:10.1016/s2665-9913(24)00090-0
- Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008;17(5):412–5. doi:10.1177/0961203308090026
- Kiani AN, Post WS, Magder LS, Petri M. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(11):2071–9. doi:10.1093/rheumatology/ker285
- Guzmán-Martínez G, Marañón C. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Front Immunol 2022;13:974826. doi:10.3389/fimmu.2022.974826
- Duarte-García A, Hocaoglu M, Valenzuela-Almada M, Osei- Onomah SA, Dabit JY, Sanchez-Rodriguez A, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis 2022;81(9):1260–6. doi:10.1136/annrheumdis-2022-222276
)